Crushing HIV

Richardson, Sarah
January 1997
Discover;Jan97, Vol. 18 Issue 1, p28
Reports on advances in chemotherapy against HIV infection. Mult-drug regimen; Protease inhibitors; Cost considerations; Side effects of the drug; Chances of complete remission.


Related Articles

  • Resistance, remission, and qualitative differences in HIV chemotherapy. Kirschner, Denise E.; Webb, G.F. // Emerging Infectious Diseases;Jul-Sep97, Vol. 3 Issue 3, p273 

    Presents a design of a mathematical system that models human immunodeficiency virus (HIV) multidrug chemotherapy including uninfected and infected CD4+T cells and virus population. Inclusions in the model; Indications from the simulations; Important distinction between resistance and remission;...

  • First of a new class of drugs for HIV.  // Modern Medicine;Feb96, Vol. 64 Issue 2, p38 

    Reports on the United States Food and Drug Administration's approval of the drug Saquinavir mesylate (Invirase), indicated for HIV infections. Mode of action.

  • First-line treatment of HIV infection.  // Modern Medicine;Nov96, Vol. 64 Issue 11, p33 

    Reports on the Food and Drug Administration's approval of Didanosine as a monotherapy for treating HIV infection when antiretroviral therapy is warranted.

  • Prescriptions pile up for AIDS combination therapy. Rodgers, Katie // Drug Topics;1/8/96, Vol. 140 Issue 1, p14 

    Reports on developments related to chemotherapy for advanced HIV infection. Includes the US Food & Drug Administration's approval of saquinavir protease inhibitor; Combination therapy with nucleoside analogs; Prescriptions for lamivudine.

  • High hopes. McCann, Jean // Drug Topics;Aug96, Vol. 140 Issue 15, p54 

    Reports that AIDS researchers are talking about turning HIV disease from an ultimately fatal infection into a chronic disease that can be controlled by chronic therapy. Findings on the effect of triple-drug therapy on HIV; Comparison of HIV infection to a raging fire; Treatment of patients with...

  • Dosing guidelines for foscarnet and trimetrexate.  // Formulary;Jun95, Vol. 30 Issue 6, p349 

    Presents dosing and monitoring guidelines for foscarnet sodium and trimetrexate glucuronate used to treat patients with opportunistic infections associated with HIV infection. Guidelines by the P & T Committee at the Trinity Lutheran Hospital in Kansas City, Missouri; Discussion of drugs;...

  • Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected... Spruance, Spotswood L.; Pavia, Andrew T. // Annals of Internal Medicine;03/01/97, Vol. 126 Issue 5, p355 

    Evaluates the clinical effect of stavudine monotherapy in HIV positive persons. Comparison of the effectiveness of the drug with zidovudine; Rate of clinical progression in patients receiving the drug; Resolution of neuropathy in patients receiving the drug; Toleration of patients to the drug;...

  • Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society--USA panel. Carpenter, Charles C.J.; Fischl, Margaret A.; Hammer, Scott M.; Hirsch, Martin S.; Jaconsen, Donna M.; Katzenstein, David A.; Montaner, Julio S.G.; Richman, Douglas D.; Saag, Michael S.; Schooley, Robert T.; Thompson, Melanie A.; Vella, Stefano; Yeni, Patrick G.; Volberding, Paul A. // JAMA: Journal of the American Medical Association;7/1/98, Vol. 280 Issue 1, p78 

    Provides recommendations for antiretroviral therapy for HIV infection based on information available in mid-1998. Participants; Evidence; Consenus process; Conclusions on early institution and long-term approaches to antiretroviral therapy.

  • Pentafuside shows anti-HIV activity.  // AIDS Patient Care & STDs;Jun96, Vol. 10 Issue 3, p184 

    Relates the results of a study conducted on the effect of pentafuside on HIV-infections in mice. Systemic effect of the drug; Ability of the drug to reduce the extent of HIV infection.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics